




Innovative Technologies for Oncology and Dermatology

23 September 2021



Life Sciences Forum

HARDMAN & CO.

Disclaimer

The information contained in these slides and any accompanying verbal presentation, any question and answer session and any document or material distributed at or in connection with the verbal presentation (together, the "Presentation") have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). Reliance upon this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. If any person is in any doubt as to the contents of this Presentation, they should seek independent advice from a person who is authorised for the purposes of FSMA and who specialises in advising on investments of this kind. This Presentation is being supplied to you solely for your information and does not purport to contain all information that may be required to evaluate Incanthera plc (the "Company"). This Presentation has been prepared by, and is the sole responsibility of, the Company. The directors of the Company have taken all reasonable care to ensure that the facts stated herein are true to the best of their knowledge, information and belief.

This Presentation does not constitute, or form part of, an admission document, listing particulars, a prospectus or a circular relating to the Company, nor does it constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company nor shall it or any part of it, or the fact of its distribution, form the basis of, or be relied upon in connection with, or act as any inducement to enter into any contract. Any investment in shares in the Company should only be made by you on the basis of definitive documentation in final form (which may contain different information from the information contained in this Presentation), and your own judgment as to the merits of the suitability of the shares for your purposes, having taken all such professional advice you consider necessary or appropriate in the circumstances.

No reliance may be placed for any purpose whatsoever on the information or opinions contained in this Presentation or on its completeness, accuracy or fairness thereof, nor is any responsibility accepted for any errors, misstatements in, or omission from, this Presentation or any direct or consequential loss however arising from any use of, or reliance on, this Presentation or otherwise in connection with it.

This Presentation may not be reproduced or redistributed, in whole or in part, to any other person, or published, in whole or in part, for any purpose without the prior consent of the Company. The contents of this Presentation are subject to updating, completion, revision, further verification and amendment without notice.

Past performance is not a guide to future performance.

Neither this Presentation nor any copy of it should be distributed, directly or indirectly, by any means (including electronic transmission) to any persons with addresses in the United States of America (or any of its territories or possessions) (together, the "US"), Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa, or to any corporation, partnership or other entity created or organised under the laws thereof, or in any other country outside the United Kingdom where such distribution may lead to a breach of any legal or regulatory requirement. The recipients should inform themselves about and observe any such requirements or relationship.

The Company's ordinary shares have not been, and are not expected to be, registered under the United States Securities Act 1933, as amended, (the "US Securities Act") or under the securities laws of any other jurisdiction, and are not being offered or sold, directly or indirectly, within or into the US, Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa, or to, or for the account or benefit of, any US persons or any national, citizen or resident of the US, Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa, unless such offer or sale would qualify for an exemption from registration under the US Securities Act and/or any other applicable securities laws.

This Presentation or documents referred to in it contain forward-looking statements. These statements relate to the future prospects developments and business strategies of the Company and its subsidiaries (the "Group"). Forward-looking statements are identified by the use of such terms as "believe", "could", "envisage", "estimate", "potential", "intend", "may", "plan", "will" or the negative of those, variations or comparable expressions, including references to assumptions. The forward-looking statements contained in this Presentation are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. If one or more of these risks or uncertainties materialises, or if underlying assumptions prove incorrect, the Group's actual results may vary materially from those expected, estimated or projected. Given these risks and uncertainties, potential investors should not place any reliance on forward-looking statements. These forward-looking statements speak only as at the date of this Presentation. The Company is under no obligation to, and expressly disclaims any intention to, update or revise such forward-looking statements, estimates or projections.

By accepting receipt of, attending any delivery of, or electronically accessing, the Presentation, you agree to be bound by the above limitations and conditions and, in particular, you represent, warrant and undertake to the Company that: (i) you are a Relevant Person (as defined above); (ii) you will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose and (iii) you have read and agree to comply with the contents of this disclaimer.



Novel Cancer Medicines through Targeted Technology

Company Heritage

Incanthera was established as a UK oncology focused, targeted drug development company originating from the Institute of Cancer Therapeutics, University of Bradford (UoB)

Acquiring, preparing and commercialising new oncology technologies including a Pipeline Agreement with UoB

- ✓ Multiple asset portfolio
- ✓ First commercial deal for Company's asset (EP0015) signed June 2017
- ✓ Near to market asset – Sol

Acquire, Prepare, Commercialise



Our Approach

Identify cutting edge technologies in oncology and dermatology



Acquire intellectual property rights to product opportunities



Prepare technologies to valuation realisation



Commercialise through a partner, securing deal that aims to prioritise further development, marketing and early revenues to Incanthera



The Incanthera Team



Tim McCarthy
Corporate & City
Chairman (Board)

35-year international career, CEO and CFO of public and private biotech & healthcare companies. Non-Executive Chairman of ImmuPharma plc and of 4basebio UK Societas



Simon Ward
Technology &
Development
CEO (Board)

Founder of Incanthera, former founder, CEO and CSO of private and public specialist biotech & healthcare companies



Alan Warrander
Industry & Licensing
NED (Board)

Experienced pharma and biotech executive with extensive background in global pharma drug discovery development including AstraZeneca and Wood Mackenzie



Pawel Zolniercyk
IP & Tech- Transfer
COO

IP, Tech Transfer and Project Management specialist, with over 10 years experience in IP commercialisation



Laura Brogden
Financial Control
& Governance
CFO

Associate of the Chartered Institute of Management Accounts with 20 years' industry experience. Partner of FACT3 LLP




Suzanne Brocks
Shareholders,
City & Company
Head of Communications,
Company Secretary

Accomplished financial communications specialist with over 30 years' City and PR experience, through Hill Samuel and Buchanan Communications

Growth since admission to AQSE

Month	News
February 2020	Admission to AQSE at debut price of 9.5p
July 2020	New Patent Filing for Sol Skin Cancer Technology
September 2020	Successful Results of Permeation Study
September 2020	Successful Results of Sensitisation Study
December 2020	Announcement of Interim Results
December 2020	Elevation to Apex segment of Aquis Growth Market
February 2021	Commercial Update
March 2021	Placing to raise £1.14m
May 2021	Full Year Results for year ended 31 March 2021

AQSE: INC



Source: BrighterIR

Oncology Product Pipeline

Programme			Preparation for Licensing	Licensing
Platform	Product	Indication		
Sol	Topical Cream	Skin cancers: solar keratosis (SK), melanoma (SK - \$3.4bn)*	Bioequivalence	Market Launch
EP0015	VDA & Theranostic	Lung, breast, ovarian cancers (\$5.9bn, \$15.3bn, \$1.6bn)*	Pre-clinical	Licensed to Ellipses Pharma Ltd (2017)
	Taxane	Ovarian, prostate cancers (\$1.6bn, \$8.6bn)*	Lead	
Equin	DT Diaphorase activation	Liver, brain, pancreatic cancers (\$0.5bn, \$0.35bn, \$2bn)*	Pre-clinical	
Duo-C	CYP activation	Bladder, colorectal cancers (\$0.36bn, \$8bn)*	Lead	

*Market size estimates sourced from external commercial sector reports

Focus: Sol and the Skin Cancer Challenge

Skin cancer (including solar keratosis) is the most common form of cancer in white populations, and deaths arising from invasive melanoma are on the increase.

Melanoma has increased by **45% in ten years**

Melanoma is the **fifth most common cancer** in young adults

Rates in the UK increasing by **70% in 25 to 49-year-olds** since 1990's


Source: Cancer Research UK

The global market for skin 'sun care' products is projected to reach US\$13.7 billion by 2024 (excluding pharmaceutical products, currently \$3.4bn)*

*Market size estimates sourced from external commercial sector reports

Acquire, Prepare, Commercialise

UK SKIN CANCER RATES 2004-2016
(NUMBERS PER 100,000)



Our Natural Defence

Cells have natural defence and DNA repair capabilities, but this is compromised in skin cells by UV light

A natural agent believed to enhance the skin's defences and DNA repair capabilities, to counter UV effects, has been identified



UV depletes ATP, reducing cellular energy for DNA repair



UV suppresses antitumor immune responses

MUTATIONS
CANCER

GENOMIC
STABILITY

Studies including a Phase 3 clinical trial have demonstrated that Oral Dosing of this agent:

- 

Significantly reduces progression of actinic (solar) keratoses and other pre-cancerous lesions to the more deadly melanoma forms
- 

Reduces recurrence of skin cancer in previously treated subjects prone to skin cancer development

Dermatological experts in skin cancer believe that Sol's active ingredient can reduce the incidence of actinic keratosis

Sol – Opportunities and Advantages

Opportunity – Sol

A dermatological preparation of the natural agent to offer significant advantages over oral dosing

Advantages of Sol over oral dosing

- Avoidance of known possible side effects of ingestion
- Circumvention of first-pass metabolism
- Ease of application
- Direct targeting of sun exposed tissues and lesions
- Opportunity to introduce additional UV protection
- Addition of “do-good” cosmetic skin care ingredient (e.g., anti-ageing)




VS



Sol Delivers

Two independent Proof of Principle Studies have demonstrated (Summer 2020):

- ✓ Sol exceeds the bioequivalence test using human skin penetration models (UCL School of Pharmacy)
- ✓ The formulation is non-irritant, comparable to baby sun protection products (XCellR8)



Sol delivers a safe, topical product for the prevention of solar keratosis and skin cancer

Sol – Licensing



Sol has been introduced to a selection of potential licensees

These companies fall into two groups, being concerned either with cosmetics alone or pharmaceuticals (with or without cosmetics)

Discussions with 2 global cosmetic companies have been prioritised. The Company is pleased with the ongoing progress of all these discussions

...Exploring application of expertise and technology in conjunction with key experts in dermatology for future opportunities

Investment Opportunity



Progressing commercialisation discussions: Sol

Differential Business Model

Multiple product portfolio

Established oncology pipeline

Investor support through AQSE listing

EIS/VCT qualified
